Supplement Scholar
Experimental Anti-Obesity

Adipotide

Research compound. This is not a dietary supplement. Unless it is identified as an approved prescription drug, it is not approved by the FDA for human use. This page summarizes published research for education only; we do not sell it or link to sellers.

Adipotide. Pro-apoptotic peptide that targets the vasculature of white adipose tissue in preclinical work.

How it works. Binds prohibitin on white adipose endothelium and triggers apoptosis of the supporting vasculature, leading to localized fat tissue loss.

What the research supports. 2 graded claims. Strongest: Peripheral mechanism, no central appetite effect (preclinical).

Hormonal impact. Effects on Adipose-derived hormones, Insulin sensitivity.

Side effects and interactions. 1 medication interaction listed. Serious: Nephrotoxicity (proximal tubule injury) — the major reason it has not advanced clinically.

Stacking. Pairs well with Nothing in clinical use — pre-clinical only. Avoid combining with Any chronic kidney disease.

Common forms. Available as Subcutaneous injection (research).

Community. Experiences from people who have tried Adipotide. Anecdotes are not medical advice.

Adipotide. Pro-apoptotic peptide that targets the vasculature of white adipose tissue in preclinical work.

Molecular structureC111H206N36O28S2 · 2557.2 g/mol

What it is

Adipotide is a fusion peptide combining a homing motif for white adipose vasculature with a pro-apoptotic sequence, studied as an experimental anti-obesity agent.

Also called

FTPP

How it works

Binds prohibitin on white adipose endothelium and triggers apoptosis of the supporting vasculature, leading to localized fat tissue loss.

Pathways

  • Prohibitin homing
  • Endothelial apoptosis
  • Adipose tissue regression

Effects

  • ↓White adipose tissue mass in primates decreases
  • ↓Body weight without affecting appetite centrally decreases

What the research supports

Peripheral mechanism, no central appetite effectpreclinical
Novel target — adipose vasculaturepreclinical

Strong: consistent results across large trials or meta-analyses. Moderate: several trials, mostly positive. Limited: small or mixed studies. Preclinical: animal or cell research only.

Hormonal impact

↓Adipose-derived hormonesdecreases
~Insulin sensitivitymodulates

Side effects & interactions

Common side effects

  • Limited human data

Serious

  • Nephrotoxicity (proximal tubule injury) — the major reason it has not advanced clinically

Medication interactions

Nephrotoxic agentsmoderate

Additive renal injury concern.

Check any supplement–medication combination with your pharmacist before starting.

Combines with

Pairs well

  • Nothing in clinical use — pre-clinical onlyNot appropriate for human application at this time.

Avoid combining

  • Any chronic kidney diseaseNephrotoxicity risk is the dose-limiting toxicity.

Common forms

  • Subcutaneous injection (research)

Discussion

Loading discussion…